Virtual and biomolecular screening converge on a selective agonist for GPR30.

Article Details

Citation

Copy to clipboard

Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER

Virtual and biomolecular screening converge on a selective agonist for GPR30.

Nat Chem Biol. 2006 Apr;2(4):207-12. Epub 2006 Mar 5.

PubMed ID

16520733 [ View in PubMed

]

Abstract

Estrogen is a hormone critical in the development, normal physiology and pathophysiology of numerous human tissues. The effects of estrogen have traditionally been solely ascribed to estrogen receptor alpha (ERalpha) and more recently ERbeta, members of the soluble, nuclear ligand-activated family of transcription factors. We have recently shown that the seven-transmembrane G protein-coupled receptor GPR30 binds estrogen with high affinity and resides in the endoplasmic reticulum, where it activates multiple intracellular signaling pathways. To differentiate between the functions of ERalpha or ERbeta and GPR30, we used a combination of virtual and biomolecular screening to isolate compounds that selectively bind to GPR30. Here we describe the identification of the first GPR30-specific agonist, G-1 (1), capable of activating GPR30 in a complex environment of classical and new estrogen receptors. The development of compounds specific to estrogen receptor family members provides the opportunity to increase our understanding of these receptors and their contribution to estrogen biology.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Estradiol	Estrogen receptor alpha	Ki (nM)	0.3	N/A	N/A	Details
Estradiol	Estrogen receptor beta	Ki (nM)	0.38	N/A	N/A	Details
Estradiol	G-protein coupled estrogen receptor 1	Ki (nM)	5.7	N/A	N/A	Details
Estradiol	G-protein coupled estrogen receptor 1	EC 50 (nM)	0.3	N/A	N/A	Details